2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2627

Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
Abstract Number: 2628

Hydroxychloroquine and Prednisone Have Different Effects on Antiphospholipid Antibodies in SLE, with Hydroxychloroquine Not Reducing IgA Anticardiolipin
Abstract Number: 2629

Longitudinal Analysis of Persistent Positivity of Antiphospholipid Antibodies in Systemic Lupus Erythematosus
Abstract Number: 2630

Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus
Abstract Number: 2631

Hydroxychloroquine Blood Levels Are Significantly Associated with Cardiovascular Risk Factors
Abstract Number: 2632

Rates and Predictors of Thirty-Day Readmission Among Patients Hospitalized for Systemic Lupus Erythematosus at a Single Tertiary Care Center
Abstract Number: 2633

Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Abstract Number: 2634

The Risk of Hydroxychloroquine Retinopathy in an SLE Cohort: Screening and Prevention in Clinical Practice
Abstract Number: 2635

Combined Panel of Nine Tests Has the Greatest Sensitivity but the Lowest Specificity to Detect Antiphospholipid Antibody Syndrome in Patients with Systemic Lupus Erythematosus
Abstract Number: 2636

Investigating Lupus Nephritis Patient Outcomes Receiving Belatacept Post Renal Transplant Using the UNOS Database
Abstract Number: 2637

Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Abstract Number: 2638

Tacrolimus Use in Hispanic Patients with Refractory Lupus Nephritis
Abstract Number: 2639

Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus
Abstract Number: 2640

Hematologic Activity in Systemic Lupus Erythematosus: Is Splenectomy Our Best Choice?
Abstract Number: 2641

Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].